Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1983 1
1985 2
1986 1
1987 1
1988 2
1990 1
1991 1
1992 2
1993 2
1994 3
1995 3
1996 2
1997 4
1998 1
1999 3
2000 5
2001 9
2002 4
2003 9
2004 12
2005 14
2006 13
2007 12
2008 7
2009 5
2010 11
2011 7
2012 2
2013 2
2014 12
2015 9
2016 8
2017 5
2018 10
2019 12
2020 11
2021 3
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, Gao LJ, Yang DH, Zhu DL. Feng WH, et al. J Diabetes Investig. 2019 Mar;10(2):399-407. doi: 10.1111/jdi.12888. Epub 2018 Aug 16. J Diabetes Investig. 2019. PMID: 29957886 Free PMC article. Clinical Trial.
AIMS/INTRODUCTION: To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease. MATERIALS AND METHODS: A total of 85 patients were randomly allocated to receive glic …
AIMS/INTRODUCTION: To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabet …
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N. Johnston R, et al. Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020. Health Technol Assess. 2017. PMID: 28105986 Free PMC article. Review.
In monotherapy, the three drugs do not appear cost-effective compared with gliclazide or pioglitazone, but may be competitive against sitagliptin (Januvia, Boehringer Ingelheim, Bracknell, UK). ...
In monotherapy, the three drugs do not appear cost-effective compared with gliclazide or pioglitazone, but may be competitive against …
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, Houweling ST, Bilo HJ, Kleefstra N. Landman GW, et al. PLoS One. 2014 Feb 12;9(2):e82880. doi: 10.1371/journal.pone.0082880. eCollection 2014. PLoS One. 2014. PMID: 24533045 Free PMC article. Review.
Compared to other glucose lowering agents except metformin, gliclazide was slightly more effective (-0.13% (95%CI: -0.25, -0.02, I(2) 55%)). One out of 2,387 gliclazide users experienced a severe hypoglycemic event, whilst also using insulin. ...
Compared to other glucose lowering agents except metformin, gliclazide was slightly more effective (-0.13% (95%CI: -0.25, -0.02, I(2) …
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. ADVANCE Collaborative Group, et al. N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6. N Engl J Med. 2008. PMID: 18539916 Free article. Clinical Trial.
METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or le …
METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, …
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
Chan SP, Colagiuri S. Chan SP, et al. Diabetes Res Clin Pract. 2015 Oct;110(1):75-81. doi: 10.1016/j.diabres.2015.07.002. Epub 2015 Jul 9. Diabetes Res Clin Pract. 2015. PMID: 26361859 Review.
CONCLUSION: Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypoglycemia risk. Compared with other sulfonylureas, HbA1c reduction with gliclazide was not significantly different, but hypoglycemia ri …
CONCLUSION: Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypog …
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH. Domecq JP, et al. J Clin Endocrinol Metab. 2015 Feb;100(2):363-70. doi: 10.1210/jc.2014-3421. Epub 2015 Jan 15. J Clin Endocrinol Metab. 2015. PMID: 25590213 Free PMC article. Review.
Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide ( …
Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperido …
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
Mbanya JC, Al-Sifri S, Abdel-Rahim A, Satman I. Mbanya JC, et al. Diabetes Res Clin Pract. 2015 Aug;109(2):226-32. doi: 10.1016/j.diabres.2015.04.030. Epub 2015 May 8. Diabetes Res Clin Pract. 2015. PMID: 26003888 Review.
CONCLUSION: Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia. Gliclazide is an effective oral antidiabetic that may be suitable for the management of patients w …
CONCLUSION: Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of expe …
Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC. Zhang YS, et al. Front Endocrinol (Lausanne). 2021 Oct 14;12:735824. doi: 10.3389/fendo.2021.735824. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34721294 Free PMC article.
Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nateglinide) may increase the risk of fracture, while others (such as dulaglutide, exenatide, liraglutide, semaglutide, lixisenatide, linagliptin, alog …
Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nateglinide …
SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.
Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MMH, Joles JA, Bjornstad P, van Raalte DH. Suijk DLS, et al. Clin J Am Soc Nephrol. 2022 May;17(5):663-671. doi: 10.2215/CJN.11480821. Epub 2022 Mar 23. Clin J Am Soc Nephrol. 2022. PMID: 35322793 Free PMC article. Clinical Trial.
First, in the Renoprotective Effects of Dapagliflozin in Type 2 Diabetes study, 44 people with type 2 diabetes were randomized to dapagliflozin or gliclazide for 12 weeks. Plasma uric acid, fractional uric acid excretion, and hemodynamic kidney function were measured in th …
First, in the Renoprotective Effects of Dapagliflozin in Type 2 Diabetes study, 44 people with type 2 diabetes were randomized to dapagliflo …
Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
Negro R, Greco EL, Greco G. Negro R, et al. Exp Clin Endocrinol Diabetes. 2019 Apr;127(4):215-219. doi: 10.1055/s-0043-122383. Epub 2018 Mar 20. Exp Clin Endocrinol Diabetes. 2019. PMID: 29558784 Clinical Trial.
AIM: We investigated the effect of alogliptin and gliclazide on endothelial progenitor cells (EPCs) in type 2 diabetes. ...CONCLUSIONS: Both alogliptin and gliclazide demonstrated a beneficial effect in increasing EPCs in poorly controlled type 2 diabetes. ...
AIM: We investigated the effect of alogliptin and gliclazide on endothelial progenitor cells (EPCs) in type 2 diabetes. ...CONCLUSION …
198 results

Searches related to "gliclazide"